In Vivo Fate of CXCR2-Overexpressing Mesenchymal Stromal/Stem Cells in Pulmonary Diseases Monitored by Near-Infrared Region 2 Imaging

doi:10.1021/acsami.3c01741

	In Vivo Fate of CXCR2-Overexpressing Mesenchymal Stromal/Stem Cells in Pulmonary Diseases Monitored by Near-Infrared Region 2 Imaging
	Yang, Huiying 1; Wu, Qingxia2 ; Li, Jinwei2 ; Chen, Qimingxing2 ; Su, Lili2 ; He, Xiaoyan2 ; Li, Jianfeng2 ; Qiu, Xiaoyan 1
	2023-04
发表期刊	ACS APPLIED MATERIALS & INTERFACES (IF:8.3[JCR-2023],8.7[5-Year])
ISSN	1944-8244
EISSN	1944-8252
卷号	15 期号:17 页码:20742-20752
发表状态	已发表
DOI	10.1021/acsami.3c01741
摘要	Lung-associated diseases pose a huge threat to human society. Mesenchymal stromal/stem cells (MSCs) hold great promise in the treatment of pulmonary diseases loading. However, intravenous injection of MSCs often resulted in limited lesion tropism and apparent off-target accumulation. The IL-8-CXCR1/2 chemokine axis has been shown to be involved in progression of diseases including lung cancer and acute lung injury (ALI). Herein, we took advantage of this chemokine axis to enhance the homing of MSCs to cancerous and inflammation lesions. The in vivo distribution of MSCs was further monitored real-time by near-infrared region 2 (NIR-II) imaging owing to its outstanding performance in deep tissue imaging. Specifically, a new high-brightness D-A-D NIR-II dye, LJ-858, was synthesized and coprecipitated with a poly(D,L-lactic acid) polymer to form LJ-858 nanoparticles (NPs) with a relative quantum yield of 14.978%. LJ858 NPs can efficiently label MSCs, and the NIR-II signal can be stable for 14 days without compromising the cell viability. Subcutaneous tracking of labeled MSCs showed no significant decline of NIR-II intensity within 24 h. The enhanced tropism of CXCR2-overexpressing MSCs to A549 tumor cells and the inflamed lung tissue was demonstrated through transwell models. The in vivo and ex vivo NIR-II imaging results further validated the significantly enhanced lesion retention of MSCCXCR2 in the lung cancer and ALI models. Taken together, this work reported a robust strategy to enhance the pulmonary disease tropism by the IL-8CXCR1/2 chemokine axis. In addition, in vivo distribution of MSCs was successfully visualized by NIR-II imaging, which provides more insights into optimizing protocols for MSC-based therapies in the future.
关键词	MSCs CXCR2 NIR-II lung cancer ALI
URL	查看原文
收录类别	SCI ; EI
语种	英语
资助项目	Natural Science Foundation of Shanghai[21ZR1442200] ; Huashan Hospital startup grant[850]
WOS研究方向	Science & Technology - Other Topics ; Materials Science
WOS类目	Nanoscience & Nanotechnology ; Materials Science, Multidisciplinary
WOS记录号	WOS:000975424900001
出版者	AMER CHEMICAL SOC
EI入藏号	20231814040445
EI主题词	Lactic acid
EI分类号	461.2 Biological Materials and Tissue Engineering ; 461.6 Medicine and Pharmacology ; 723.1 Computer Programming ; 802.2 Chemical Reactions ; 804.1 Organic Compounds
原始文献类型	Journal article (JA)
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/292199
专题	生命科学与技术学院_PI研究组_李剑峰组生命科学与技术学院_硕士生生命科学与技术学院_博士生 iHuman研究所_PI研究组_张潇洁组
通讯作者	Li, Jinwei; Li, Jianfeng; Qiu, Xiaoyan
作者单位	1.Fudan Univ, Huashan Hosp, Dept Pharm, Shanghai 200040, Peoples R China 2.ShanghaiTech Univ, Gene Editing Ctr, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Yang, Huiying,Wu, Qingxia,Li, Jinwei,et al. In Vivo Fate of CXCR2-Overexpressing Mesenchymal Stromal/Stem Cells in Pulmonary Diseases Monitored by Near-Infrared Region 2 Imaging[J]. ACS APPLIED MATERIALS & INTERFACES,2023,15(17):20742-20752.
APA	Yang, Huiying.,Wu, Qingxia.,Li, Jinwei.,Chen, Qimingxing.,Su, Lili.,...&Qiu, Xiaoyan.(2023).In Vivo Fate of CXCR2-Overexpressing Mesenchymal Stromal/Stem Cells in Pulmonary Diseases Monitored by Near-Infrared Region 2 Imaging.ACS APPLIED MATERIALS & INTERFACES,15(17),20742-20752.
MLA	Yang, Huiying,et al."In Vivo Fate of CXCR2-Overexpressing Mesenchymal Stromal/Stem Cells in Pulmonary Diseases Monitored by Near-Infrared Region 2 Imaging".ACS APPLIED MATERIALS & INTERFACES 15.17(2023):20742-20752.